Bimatoprost 0.03%/Timolol 0.5% Preservative-Free Ophthalmic

Total Page:16

File Type:pdf, Size:1020Kb

Bimatoprost 0.03%/Timolol 0.5% Preservative-Free Ophthalmic BJO Online First, published on March 25, 2014 as 10.1136/bjophthalmol-2013-304064 Clinical science Br J Ophthalmol: first published as 10.1136/bjophthalmol-2013-304064 on 25 March 2014. Downloaded from Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial Ivan Goldberg,1 Rafael Gil Pina,2 Aitor Lanzagorta-Aresti,3 Rhett M Schiffman,4 Charlie Liu,4 Marina Bejanian4 ▸ Additional material is ABSTRACT As topical medications are normally dispensed published online only. To view Aim To compare the efficacy and safety of single-dose from multiuse bottles, preservative (typically ben- please visit the journal online (http://dx.doi.org/10.1136/ bimatoprost 0.03%/timolol 0.5% preservative-free (PF) zalkonium chloride, BAK) is employed to maintain bjophthalmol-2013-304064). ophthalmic solution with bimatoprost 0.03%/timolol sterility. Although many patients use preservative- 0.5% ophthalmic solution in patients with open-angle containing medications without adverse effects,10 11 1Department of Ophthalmology, University of glaucoma or ocular hypertension. some become sensitive to ophthalmic preserva- 12 13 Sydney, Sydney Eye Hospital, Methods In this multicentre, randomised, parallel- tives. A single-dose, preservative-free (PF) oph- Sydney, Australia group study, patients were randomised to bimatoprost/ thalmic fixed combination would benefit this patient 2 Clinica Oftalmologica Rafael timolol PF or bimatoprost/timolol once daily in the subpopulation. Our study evaluated the safety and Gil Pina, Huelva, Spain fi fi fi 3Fundacion Oftalmologica Del morning for 12 weeks. Primary ef cacy endpoints, ef cacy of a new PF xed-combination bimatoprost Mediterraneo, Valencia, Spain reflecting differing regional regulatory requirements, 0.03%/timolol 0.5% (bimatoprost/timolol PF; 4Allergan, Inc., Irvine, included change from baseline in worse eye intraocular Ganfort SD) for patients who are sensitive or aller- California, USA (at the time pressure (IOP) in the per-protocol population at week gic to preservatives. the study was conducted) 12, and the average eye IOP at weeks 2, 6 and 12 in Correspondence to the intent-to-treat population. METHODS Professor Ivan Goldberg, Results 561 patients were randomised (278 to Study design and participants Department of Ophthalmology, bimatoprost/timolol PF; 283 to bimatoprost/timolol); This was a phase 3, multicentre, double-masked, University of Sydney, Sydney 96.3% completed the study. Both treatment groups randomised, active-controlled study (ClinicalTrials. Eye Hospital, Floor 4, 187 fi Macquarie Street, Sydney, NSW showed statistically and clinically signi cant mean gov: NCT01177098) conducted in 55 centres in 2000, Australia; decreases from baseline in worse eye IOP and in average Australia, Czech Republic, Germany, Hungary, eyegoldberg@gmail.com eye IOP at all follow-up time points (p<0.001). Israel, Russia, Spain, UK and the USA. It complied Bimatoprost/timolol PF met all pre-established criteria for with Good Clinical Practice guidelines and was http://bjo.bmj.com/ Received 22 July 2013 non-inferiority and equivalence to bimatoprost/timolol. approved by an institutional review board or inde- Revised 25 January 2014 Accepted 15 February 2014 Ocular adverse events were similar between treatment pendent ethics committee. Written informed groups, with conjunctival hyperaemia being the most consent was obtained from each patient prior to frequent. Most were mild or moderate in severity. study enrolment. Conclusions Bimatoprost/timolol PF demonstrated Eligible participants were aged at least 18 years, non-inferiority and equivalence in IOP lowering had OHT or open-angle glaucoma, and were either fi compared with bimatoprost/timolol, with no signi cant treatment-naive with IOP >24 mm Hg in at least on September 28, 2021 by guest. Protected copyright. differences in safety and tolerability. one eye or were receiving IOP treatment that was Trial registration number NCT01177098. considered to be inadequate (IOP >18 mm Hg in at least one eye). At baseline, following 4 days’ to 4 weeks’ washout of IOP-lowering medications, patients were required to have an IOP of 22– INTRODUCTION 30 mm Hg in each eye, with IOP asymmetry Bimatoprost is a synthetic prostamide,1 which is <4 mm Hg between eyes and a best-corrected highly effective in lowering intraocular pressure visual acuity (BCVA) equivalent to a Snellen score (IOP) in patients with ocular hypertension (OHT) of 20/100 or better in each eye. The minimum or open-angle glaucoma.2 If single agents fail to washout period was 4 days for parasympathomi- achieve a satisfactory IOP reduction or are intoler- metics and topical or systemic carbonic anhydrase able, fixed combinations are preferred to multiple inhibitors, 2 weeks for sympathomimetics and α concurrent medications.34The fixed combination agonists, and 4 weeks for β-adrenergic blocking of bimatoprost 0.03%/timolol 0.5% (bimatoprost/ agents, combination products and prostaglandin To cite: Goldberg I, Gil timolol; Ganfort, Allergan, Irvine, California, USA) agonists. Primary exclusion criteria were: uncon- Pina R, Lanzagorta-Aresti A, administered once daily has been shown to be well trolled systemic disease; known allergy or sensitiv- et al. Br J Ophthalmol Published Online First: tolerated and to be effective in patients with inad- ity to the study medications or their components; [please include Day Month equate IOP lowering with a single ocular hypoten- introduction or anticipated alteration in ongoing – Year] doi:10.1136/ sive medication,5 8 as well as in treatment-naive use of medication that may have a significant effect bjophthalmol-2013-304064 patients.9 on IOP; ocular surface findings (eg, hyperaemia or GoldbergCopyright I, et al. Br Article J Ophthalmol author2014;0 :1(or–6. doi:10.1136/bjophthalmol-2013-304064their employer) 2014. Produced by BMJ Publishing Group Ltd under licence. 1 Clinical science Br J Ophthalmol: first published as 10.1136/bjophthalmol-2013-304064 on 25 March 2014. Downloaded from irritation equal to +0.5 (trace) or greater) in either eye; history A two-sided 95% CI for the treatment difference was con- (within 6 months prior to baseline) of any ocular anterior structed from the ANOVA model with an estimated treatment segment laser or other intraocular surgery in either eye; required difference based on least squares means. Bimatoprost/timolol PF chronic use of other ocular medications during the study; visual would be considered equivalent to bimatoprost/timolol if the field loss that in the opinion of the investigator was functionally 95% CI upper limit was ≤1.5 mm Hg and the lower limit was significant or evidence of progressive visual field loss; or antici- ≥–1.5 mm Hg at all time points, and the upper limit was pated wearing of contact lens in either eye during the study. ≤1.0 mm Hg and the lower limit was ≥–1.0 mm Hg at the majority of time points. Treatment and assessments The proportion of responders, defined as patients with a Eligible patients were randomly assigned (1:1) at each investiga- ≥20% reduction in worse eye IOP from the corresponding hour tor site (by automated interactive voice/web response systems) to (hour 0, 2 or 8) of baseline at week 12, was also analysed in the once-daily treatment in the morning in each eye with bimato- ITT population. Treatment group differences were assessed prost/timolol PF or bimatoprost/timolol for 12 weeks. The ran- using Pearson’s χ2 test. domisation scheme was prepared by the study sponsor. Randomisation was stratified by baseline mean diurnal IOP Sample size calculations (≤24 mm Hg or >24 mm Hg). Patients were dispensed study Sample size calculations were based on a one-sided α=0.025, medication kits containing unit-dose (single-use) containers that 80% power and an assumption of no difference between treat- were identical for both formulations, thereby ensuring masking ment groups. The sample size needed to demonstrate the non- of patients, investigators and evaluators. The treatment was to inferiority of worse eye IOP (1.5 mm Hg inferiority margin) be instilled in the morning to facilitate timing of study assess- and equivalence in average eye IOP (equivalence limit of ments. Compliance was assessed by the investigator who kept a ±1.5 mm Hg at all follow-up time points, and of ±1.0 mm Hg detailed inventory of the units dispensed and reconciled con- at the majority of follow-up time points) were estimated. The tainers returned to the study site. largest sample size from these estimates ensured adequate power IOP was measured using a slit lamp-mounted Goldmann for all criteria, given an expected 10% dropout rate. applanation tonometer, and a two-person masked reading method (ie, one adjusts the dial in a masked fashion while the RESULTS second reads and records the value) at 8:00 (hour 0), 10:00 and Baseline demographics and patient characteristics 16:00 at baseline, and at weeks 2, 6 and 12. Two consecutive The study was initiated on 31 October 2010 and completed on measurements were taken of each eye; if these two measure- 21 February 2012. A total of 561 patients were enrolled with ments differed by ≤1 mm Hg, the IOP for the given eye was the 540 (96.3%) completing the study; 278 were randomised to average of the two readings. If the difference between measure- bimatoprost/timolol PF and 283 were randomised to bimato- ments was >1 mm Hg, a third measurement was made, and the prost/timolol (see online supplementary figure S1). The demo- IOP for the given eye was the median of the three readings. graphic and baseline data did not show any significant Safety parameters included adverse events (AEs; coded using differences between the groups (table 1). the Medical Dictionary for Regulatory Activities V.14.1), biomi- croscopy, fundus examinations (including vertical cup/disc Efficacy ratio), macroscopic bulbar conjunctival hyperaemia (graded by Worse eye PP analysis http://bjo.bmj.com/ gross inspection in comparison with standard photographs), At baseline, there were no statistically or clinically significant dif- visual acuity, visual field measurements and vital signs.
Recommended publications
  • Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS ORIGINAL ARTICLE Volume 00, Number 0, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/jop.2013.0075 Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits Ama´lia Turner Giannico,1 Leandro Lima,1 Heloisa Helena Abil Russ,2 and Fabiano Montiani-Ferreira1 Abstract Purpose: Prostaglandin analogues (PGA) are ocular hypotensive agents used for the treatment of glaucoma. Hypertrichosis of the eyelashes has been reported in humans as a side effect. Eyelash growth was investigated with clinical trials in people using bimatoprost. Scattered reports of eyelash growth during the treatment of glaucoma with other PGA are also found in the literature. We investigated the effect of 4 different topical PGA on eyelash length. Methods: Forty New Zealand white rabbits were divided into 4 groups and received daily topical application of bimatoprost, tafluprost, travoprost, and latanoprost in the left eye for 4 weeks. The right eye received no treatment. Eyelash length was measured in both eyes before and after treatment using a stainless steel digital caliper. Results: Bimatoprost and tafluprost groups had significant increases in eyelash length. We did not observe significant eyelash growth in rabbits receiving travoprost and latanoprost after 1 month of treatment. Conclusions: Today, only bimatoprost is approved for growing eyelashes, and our research shows that ta- fluprost could be further explored by the cosmetic and pharmaceutical industry. Additional research using travoprost and latanoprost as agents for eyelash growth should be performed in the future using prolonged treatment periods to determinate whether or not these PGA induce eyelash growth, and investigate other possible side effects.
    [Show full text]
  • OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist As an Effective and Safe Modality for the Treatment of Pret
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/05/18/jpet.118.247668.DC1 1521-0103/366/2/349–364$35.00 https://doi.org/10.1124/jpet.118.247668 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:349–364, August 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics OBE022, an Oral and Selective Prostaglandin F2a Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor s Oliver Pohl, André Chollet, Sung Hye Kim, Lucia Riaposova, François Spézia, Frédéric Gervais, Philippe Guillaume, Philippe Lluel, Murielle Méen, Frédérique Lemaux, Vasso Terzidou, Phillip R. Bennett, and Jean-Pierre Gotteland ObsEva SA, Plan-les-Ouates, Geneva, Switzerland (O.P., A.C., J.-P.G.); Imperial College London, Parturition Research Group, Institute of Reproductive and Developmental Biology,HammersmithHospitalCampus,EastActon,London,UnitedKingdom(S.H.K.,L.R., V.T., P.R.B.); Citoxlab, Evreux, France (F.S., F.G.); Porsolt Research Laboratory, Le Genest-Saint-Isle, France (P.G.); Urosphere SAS, Toulouse, France (P.L., M.M.); BioTrial, Rennes, France (F.L.); and André Chollet Consulting, Tannay, Switzerland (A.C.) Downloaded from Received February 26, 2018; accepted May 15, 2018 ABSTRACT Preterm birth is the major challenge in obstetrics, affecting aggregation. In in vitro studies, OBE002 inhibited sponta- ∼ 10% of pregnancies. Pan-prostaglandin synthesis inhibitors neous, oxytocin- and PGF2a-induced human myometrial jpet.aspetjournals.org [nonsteroidal anti-inflammatory drugs (NSAIDs)] prevent preterm contractions alone and was more effective in combination labor and prolong pregnancy but raise concerns about fetal renal with atosiban or nifedipine.
    [Show full text]
  • Success of Prostaglandin E2 in Structure–Function Is a Challenge for Structure-Based Therapeutics
    COMMENTARY Success of prostaglandin E2 in structure–function is a challenge for structure-based therapeutics Charles N. Serhan*† and Bruce Levy*‡ *Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine and ‡Critical Care and Pulmonary Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115 rostaglandin (PG) E2 is almost ubiquitous in humans and evokes potent diverse actions. Utility is the price of its perfec- Ption. PGE is a founding member of the 2 PGs, a class of mediators that belongs to the still growing family of bioactive au- tacoids known as the eicosanoids (1–3). The main classes include enzymatically generated products such as thrombox- anes, leukotrienes, lipoxins, and EETs, as well as others that are produced via nonenzymatic mechanisms, e.g., isopros- tanes and cyclopentaeone PGs that are increasing in number and appreciation (4, 5). PGE2 regulates key responses in the major human systems including re- productive, gastrointestinal, neuroendo- crine, and immune (Fig. 1). Formed by conversion of arachidonic acid via cyclo- oxygenase (COX) and specific synthases, Fig. 1. Diverse actions of PGE2 and selective targeted biosynthesis in inflammation. (Inset) Eicosanoid family major enzymatic classes of cyclooxygenases and lipoxygenase pathways (see text for details). PGE2 stereospecifically exerts potent (nano- to micromolar range) tissue- and cell type-selective actions (1–6). The importance of PGs in inflammation was from protecting gastrointestinal mucosa electrophoresis that this lipid-soluble brought into view by the discovery of J. to regulating smooth muscle and fever, activity behaved as an acid. Vane and colleagues (7) that nonsteroi- set a steep challenge for designer drug Bergstro¨m’s main research was in bile dal antiinflammatory drugs (NSAIDs) hunters to achieve, namely selectivity acids and steroids.
    [Show full text]
  • Effect of Bimatoprost on Intraocular Pressure in Prostaglandin FP Receptor Knockout Mice
    Effect of Bimatoprost on Intraocular Pressure in Prostaglandin FP Receptor Knockout Mice Jonathan G. Crowston,1 James D. Lindsey,1 Christy A. Morris,1 Larry Wheeler,2 Felipe A. Medeiros,1 and Robert N. Weinreb1 PURPOSE. To determine the effect of bimatoprost on intraocular ing are not known, it has been suggested that bimatoprost pressure in the prostaglandin FP receptor knockout mouse. fundamentally differs from latanoprost, by lowering IOP ETHODS ␮ ␮ through mechanisms that are independent of FP receptor sig- M . The IOP response to a single 1.2- g(4 L) dose of 5 bimatoprost was measured in the treated and untreated fellow naling. However, there is considerable controversy regarding eyes of homozygote (FPϩ/ϩ, n ϭ 9) and heterozygote (FPϮ, n the role of FP receptor signaling, because bimatoprost has ϭ been shown to bind and activate the FP receptor in cultured 10) FP-knockout mice, as well as in wild-type C57BL/6 mice 6 (FPϩ/ϩ, n ϭ 20). Serial IOP measurements were also per- human trabecular meshwork and human ciliary muscle cells. Measurement of aqueous humor dynamics in the mouse eye formed after topical bimatoprost in a separate generation of 7 homozygous FP-knockout mice and wild-type littermate con- has been detailed recently. The FP knockout mouse, gener- trol animals (n ϭ 4 per group). Aqueous humor protein ated by homologous translocation with a target vector that ␤ concentrations were measured to establish the state of the replaces the second exon of the FP gene with the -galactosi- blood–aqueous barrier. Tissue, aqueous humor and vitreous dase and neomycin-resistance gene, was produced to demon- strate the critical role of the interaction of PGF2␣ with FP concentrations of bimatoprost, latanoprost, and their C-1 free 8 acids were determined by liquid chromatography and tandem receptors in the initiation of parturition in pregnant mice.
    [Show full text]
  • Effect of Latanoprost Or 8-Iso Prostaglandin E2 Alone and in Combination on Intraocular Pressure in Glaucomatous Monkey Eyes
    LABORATORY SCIENCES Effect of Latanoprost or 8-iso Prostaglandin E2 Alone and in Combination on Intraocular Pressure in Glaucomatous Monkey Eyes Rong-Fang Wang, MD; Steven M. Podos, MD; Janet B. Serle, MD; Thomas W. Mittag, PhD; F. Ventosa, MD; Bernard Becker, MD Objective: To evaluate the possible additivity of the ef- duction of IOP of 4.0 ± 0.6 mm Hg was produced when fects of latanoprost and 8-iso prostaglandin E2 (8-iso PGE2) 8-iso PGE2 was added to latanoprost and of 3.0 ± 0.7 on intraocular pressure (IOP) in monkey eyes with laser- mm Hg was produced when latanoprost was added to 8-iso induced glaucoma. PGE2 on day 13 before the morning dosing. Combina- tion therapy with both agents caused maximum IOP re- Methods: The IOP was measured hourly for 6 hours be- ductions from baseline of 11.3 ± 3.0 mm Hg (33%) (P,.05) ginning at 9:30 AM on day 1 (baseline day), days 6 and 7 (latanoprost with 8-iso PGE2 added) and of 9.8 ± 1.3 , (single-agent therapy), and days 13 and 14 (combination mm Hg (31%) (P .01) (8-iso PGE2 with latanoprost added) therapy with both agents). Following 1 day of baseline mea- on day 14. surement, 4 monkeys with unilateral glaucoma received monotherapy twice daily with either 1 drop of 0.005% la- Conclusion: Latanoprost and 8-iso PGE2 have an addi- tanoprost, or 0.1% 8-iso PGE2, 25 µL, at 9:30 AM and 3:30 tive effect on IOP in glaucomatous monkey eyes.
    [Show full text]
  • Effects of Prostaglandin F2α (Pgf2α) on Cell-Death Pathways in the Bovine Corpus Luteum
    Jonczyk et al. BMC Veterinary Research (2019) 15:416 https://doi.org/10.1186/s12917-019-2167-3 RESEARCH ARTICLE Open Access Effects of prostaglandin F2α (PGF2α) on cell- death pathways in the bovine corpus luteum (CL) Agnieszka Walentyna Jonczyk, Katarzyna Karolina Piotrowska-Tomala* and Dariusz Jan Skarzynski Abstract Background: Prostaglandin F2α (PGF2α) may differentially affect viability of luteal cells by inducing either proliferation or cell death (via apoptosis or necroptosis). The diverse effects of PGF2α may depend on its local vs. systemic actions. In our study, we determined changes in expression of genes related to: (i) apoptosis: caspase (CASP) 3, CASP8, BCL2 associated X (BAX), B-cell lymphoma 2 (BCL2) and (ii) necroptosis: receptor-interacting protein kinase (RIPK) 1, RIPK3, cylindromatosis (CYLD), and mixed lineage kinase domain-like (MLKL) in the early and mid-stage corpus luteum (CL) that accompany local (intra-CL) vs. systemic (i.m.) analogue of PGF2α (aPGF2α) actions. Cows at day 4 (n = 24) or day 10 (n = 24) of the estrous cycle were treated by injections as follows: (1) systemic saline, (2) systemic aPGF2α (25 mg; Dinoprost), (3) local saline, (4) local aPGF2α (2.5 mg; Dinoprost). After 4 h, CLs were collected by ovariectomy. Expression levels of mRNA and protein were investigated by RT-q PCR, Western blotting and immunohistochemistry, respectively. Results: We found that local and systemic administration of aPGF2α in the early-stage CL resulted in decreased expression of CASP3 (P < 0.01), but CASP8 mRNA expression was up-regulated (P < 0.05). However, the expression of CASP3 was up-regulated after local aPGF2α treatment in the middle-stage CL, whereas systemic aPGF2α administration increased both CASP3 and CASP8 expression (P < 0.01).
    [Show full text]
  • New Zealand Data Sheet 1. Product Name 2. Qualitative
    NEW ZEALAND DATA SHEET BIMATOPROST MULTICHEM 1. PRODUCT NAME Bimatoprost multichem 0.3 mg/mL eye drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL contains 0.3 mg bimatoprost. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Bimatoprost multichem eye drops are a clear, isotonic, colourless, sterile ophthalmic solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Bimatoprost multichem is indicated as monotherapy for the reduction of elevated intraocular pressure (IOP) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents. 4.2 Dose and method of administration Monotherapy The recommended dose is one drop of Bimatoprost multichem in the affected eye(s) once daily, administered in the evening. Adjunctive therapy The recommended dose is one drop of Bimatoprost multichem in the affected eye(s) once daily, administered in the evening. More frequent administration has not been shown to provide increased efficacy. If more than one topical ophthalmic medication is to be used, the other medication should not be used within 5 minutes of using Bimatoprost multichem eye drops. In order to minimise systemic absorption of Bimatoprost multichem eye drops, patients should be instructed to apply pressure to the tear duct immediately following administration of the drug. Paediatric use Safety and effectiveness in patients below 18 years of age has not been established. Use in elderly No dosage adjustment in elderly patients is necessary. 4.3 Contraindications Bimatoprost multichem eye drops are contraindicated in patients with hypersensitivity to bimatoprost or to any component of the medication.
    [Show full text]
  • Treatment of Eyebrow Hypotrichosis Using Bimatoprost: a Randomized, Double-Blind, Vehicle-Controlled Pilot Study
    ORIGINAL ARTICLE Treatment of Eyebrow Hypotrichosis Using Bimatoprost: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study † KENNETH R. BEER, MD,* HILLARY JULIUS, PA,* MONICA DUNN, RN,* AND FRED WILSON,MS BACKGROUND The Food and Drug Administration has approved bimatoprost ophthalmic solution (0.03%) for the treatment of eyelash hypotrichosis. Previous reports of its efficacy in eyebrow hypotrichosis are anecdotal. OBJECTIVE To assess the efficacy and safety of bimatoprost 0.03% ophthalmic solution applied to the eyebrows in a randomized, double-blind, vehicle-controlled study. METHODS Subjects (n = 20) with mild to moderate eyebrow hypotrichosis enrolled in the study. One group (Bim) applied bimatoprost to each eyebrow daily for 9 months, and another applied vehicle nightly to each eyebrow for 5 months. Subjects in the latter group were re-randomized to apply bimatoprost (Veh-Bim Group) or vehicle (Veh Group) daily to each eyebrow for 4 months. The primary end point was investigator-assessed eyebrow appearance; secondary end points were subject-reported outcomes. RESULTS Investigator assessments showed significant improvements from baseline to 6 (p = .002) and 7 (p = .005) months for the eyebrows treated with bimatoprost. p-Values for the Veh-Bim and Veh groups were not significant at any time point. End-of-study subject satisfaction with eyebrow fullness or thickness and darkness or color was greater in the Bim group than in the Veh group. Adverse effects were not observed. CONCLUSION Bimatoprost 0.03% ophthalmic solution applied daily for 9 months improves the appearance of eyebrows noticeably more than vehicle, without side effects. This study was funded with a research grant by Allergan, Inc.
    [Show full text]
  • API Manufacturing
    API Manufacturing The Importance of Process Understanding When it comes to process understanding and commercial manufacturing, no other manufacturer can match Cayman’s knowledge of prostaglandin chemistry. We are the industry leaders in prostaglandin synthesis with over 30 years of experience. Our expert chemists use this knowledge daily to synthesize commercially available eicosanoids as active pharmaceutical ingredients (APIs). Our talented team of scientists in Ann Arbor, Michigan, USA and Neratovice, Czech Republic has filed numerous patents for the complex synthesis and commercial manufacture of over seven APIs with additional compounds currently under development. OPH Cayman’s Center of Excellence in Ann Arbor focuses primarily on the synthesis, scale-up, and registration of new API manufacturing processes. Once registration batches have been completed, the GMP portion of the process and all supporting documentation are transferred to our commercial manufacturing Center of Excellence in Neratovice. The facility at Cayman Pharma has over 30 years of commercial prostaglandin and eicosanoid registration and manufacturing experience, is ISO certified, and has an excellent track record with customers and regulatory authorities VA S worldwide, including being US FDA and EMA compliant. Commercial API production We currently manufacture the following APIs according to the latest ICH and CGMP requirements for commercial distribution. Contact our sales department for more information about pricing and availability. VET · CGMP Bimatoprost · CGMP Latanoprost · CGMP Tafluprost · CGMP Travoprost · CGMP Epoprostenol (sodium salt) CS · CGMP (+)-Cloprostenol (sodium salt) · CGMP (±)-Cloprostenol (sodium salt) Development API production · Alfaprostol · Latanoprostene Bunod · Treprostinil (sodium salt) Cayman Pharma s.r.o. Phone: (+420) 315 664 381 GMP-API@caymanpharma.com 2019 CAYMAN PHARMA S.R.O.
    [Show full text]
  • Review Article Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
    Hindawi Journal of Ophthalmology Volume 2021, Article ID 5586719, 12 pages https://doi.org/10.1155/2021/5586719 Review Article Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients Ziyan Cai ,1 Mengdan Cao,1 Ke Liu,1 and Xuanchu Duan 2 1Department of Ophthalmology, e Second Xiangya Hospital of Central South University, Changsha, Hunan, China 2Department of Ophthalmology, Changsha Aier Eye Hospital, Changsha, Hunan, China Correspondence should be addressed to Xuanchu Duan; duanxchu@csu.edu.cn Received 22 February 2021; Accepted 18 May 2021; Published 25 May 2021 Academic Editor: Enrique Menc´ıa-Gutie´rrez Copyright © 2021 Ziyan Cai et al. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Aim. Within the clinical setting, some patients have been identified as lacking in response to PGAs. -is meta-analysis study aimed to evaluate the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in OAG/OHT patients, latanoprost nonresponders (LNRs), and the IOP-reducing efficacy and safety. Methods. A literature search was conducted on PubMed, Embase, and the Cochrane Controlled Trials Register. -e primary clinical endpoint was the number of responders at the end of the study. -e secondary clinical endpoint was the IOP reduction at the endpoint from baseline. Safety evaluation included five common adverse events: conjunctival hyperemia, hypertrichosis, ocular burning, ocular itching, and foreign-body sensation. Results. Eleven articles containing ten RCTs were included in this meta-analysis study. -e results highlighted that, in the OAG/ OHT population, there was no statistically significant difference in the responsiveness of the four PGAs.
    [Show full text]
  • High Performance Liquid Chromatography Tandem Mass Spectrometry Measurement of Bimatoprost, Latanoprost and Travoprost in Eyelash Enhancing Cosmetic Serums
    Article High Performance Liquid Chromatography Tandem Mass Spectrometry Measurement of Bimatoprost, Latanoprost and Travoprost in Eyelash Enhancing Cosmetic Serums Emilia Marchei 1, Daniela De Orsi 2, Carmine Guarino 2, Maria Concetta Rotolo 1, Silvia Graziano 1 and Simona Pichini 1,* 1 Department of Therapeutic Research and Medicines Evaluation, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy; emilia.marchei@iss.it (E.M.); mariaconcetta.rotolo@iss.it (M.C.R.); silvia.graziano@iss.it (S.G.) 2 Centro Nazionale Organismo Notificato Dispositivi e Cosmetici (ONDICO), National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy; daniela.deorsi@iss.it (D.D.O.); carmine.guarino@iss.it (C.G.) * Correspondence: simona.pichini@iss.it; Tel.: +39-06-4990-3682; Fax: +39-06-4990-2016 Academic Editors: Lidia Sautebin and Immacolata Caputo Received: 11 December 2015; Accepted: 4 February 2016; Published: 6 February 2016 Abstract: Most common prostaglandin analogs, bimatoprost, latanoprost and travoprost, are licensed for the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension, but their non approved use as eyelash enhancers is becoming popular, especially in patients with eyelashes hypotrichosis. A fast and sensitive high performance liquid chromatography tandem mass spectrometry method was developed for the measurement of bimatoprost, latanoprost and travoprost in cosmetic serums freely web-sold to increase eyelash length, thickness and darkness. The analytes and the internal standard (reserpine) were separated by reversed phase chromatography with 5 mM ammonium acetate with 0.02% formic acid (mobile phase A) and 5 mM ammonium acetate in acetonitrile/water (95/5; v/v) with 0.02% formic acid (mobile phase B) by gradient elution and detected with tandem mass spectrometry operated in multiple reaction monitoring mode.
    [Show full text]
  • Unoprostone Isopropyl (Rescula) Reference Number: HIM.PA.11 Effective Date: 09.04.18 Last Review Date: 11.19 Revision Log Line of Business: HIM
    Clinical Policy: Unoprostone Isopropyl (Rescula) Reference Number: HIM.PA.11 Effective Date: 09.04.18 Last Review Date: 11.19 Revision Log Line of Business: HIM See Important Reminder at the end of this policy for important regulatory and legal information. Description Unoprostone isopropyl ophthalmic solution, 0.15% (Rescula®) is a synthetic analog (docosanoid) of prostaglandin F2-alpha. FDA Approved Indication(s) Rescula is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Rescula is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Ocular Hypertension or Open-Angle Glaucoma (must meet all): 1. Diagnosis of open-angle glaucoma or ocular hypertension; 2. Failure of prostaglandin analogues (e.g., latanoprost, travoprost, bimatoprost) in combination with beta blockers (e.g., timolol), unless contraindicated or clinically significant adverse effects are experienced; 3. Age ≥ 18 years; 4. Dose does not exceed 1 bottle per 35 days. Approval duration: 12 months B. Other diagnoses/indications 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace. II. Continued Therapy A. Ocular Hypertension or Open-Angle Glaucoma (must meet all): 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; 2.
    [Show full text]